^
Association details:
| Biomarker: | RET M918T |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | motesanib (AMG 706) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Anti-tumor activity of motesanib in a medullary thyroid cancer model
Excerpt:
...motesanib inhibited the activity of wild-type Ret (IC(50)=66 nM), while it had limited activity against mutant Ret C634W (IC(50)=1100 nM) or Ret M918T (IC(50)>2500 nM)….motesanib inhibited thyroid tumor xenograft growth predominantly through inhibition of angiogenesis and possibly via a direct inhibition of VEGFR2 and Ret expressed on tumor cells.
DOI:
10.3275/7609
